Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis

• Published in: BMC infectious diseases Vol. 21; no. 1; p. 74
• Main Authors: Li, Zhouqi, Zhuang, Hemu, Wang, Guannan, Wang, Hui, Dong, Ying
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.01.2021; BioMed Central; BMC
• Subjects: Adult; Africa - epidemiology; Americas - epidemiology; Anti-Bacterial Agents - therapeutic use; Antibiotics; Asia, Southeastern - epidemiology; Bacteremia; Bacteremia - drug therapy; Bacteremia - epidemiology; Bacteremia - microbiology; Bacteria; Bias; Cancer; Cancer patients; Cancer therapies; Child; Comorbidity; Confidence intervals; Cross Infection - drug therapy; Cross Infection - epidemiology; Cross Infection - microbiology; Drug resistance; Europe - epidemiology; Female; Gram-positive bacteria; Humans; Immunosuppression; Infections; Male; Malignancy; Management; Mediterranean Region - epidemiology; Meta-analysis; Methicillin; Methicillin-resistant Staphylococcus aureus; Methicillin-Resistant Staphylococcus aureus - isolation & purification; Minimum inhibitory concentration; Mortality; MRSA; Neoplasms - epidemiology; Neoplasms - microbiology; Neoplasms - mortality; Observational Studies as Topic; Patient outcomes; Prevalence; Prognosis; Public health; Regression analysis; Risk analysis; Risk Factors; Secondary data analysis; Software; Staphylococcal Infections - drug therapy; Staphylococcal Infections - epidemiology; Staphylococcal Infections - microbiology; Staphylococcus aureus; Staphylococcus aureus infections; Staphylococcus infections; Vancomycin; Vancomycin - therapeutic use; Asia, Southeastern; Americas; Mediterranean Region; Europe; Africa; China; Prevalence; Methicillin-resistant Staphylococcus aureus; Bacteremia; MRSA; Cancer
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-021-05763-y

Cancer patients are more likely to develop and die of bloodstream infection (BSI) than noncancer patients. Methicillin-resistant Staphylococcus aureus (MRSA), which is associated with immense mortality and economic burden worldwide, is not covered by the recommended initial antibiotic therapy for cancer patients with BSI. This systemic review was performed to estimate the global methicillin-resistant Staphylococcus aureus (MRSA) prevalence among bacteremia in patients with malignancy, and further study the predictors and mortality of cancer patients with MRSA bacteremia. The PubMed and EMBASE databases were searched for studies published from Jan. 2000 to Mar. 2020 that provided primary data on the prevalence, predictors, or mortality of MRSA bacteremia in cancer patients. A random-effects model meta-analysis was performed to estimate the pooled prevalence of MRSA with 95% confidence intervals (95% CIs). The pooled prevalence of MRSA was 3% (95% CI 2-5%) among all bloodstream infections (BSIs) and 44% (95% CI 32-57%) among S. aureus bacteremia in cancer patients. Based on geographical stratification, the pooled prevalence was 5% in Africa (95% CI 1-14%), 1% in Americas (95% CI 1-2%), 2% in Europe (95% CI 1-4%), 4% in Western Pacific (95% CI 2-7%), 8% in South-east Asia (95% CI 4-14%) and 0% in Eastern Mediterranean (95% CI 0-3%). No significant temporal change in MRSA rates was detected in this analysis (R  = 0.06; P = 0.24). Predictors for MRSA BSIs among cancer patients were identified by comparison with their methicillin-susceptible counterparts, and they were mainly related to healthcare-associated infections and immunosuppression. Finally, the 60-day mortality in adult cancer patients with MRSA BSIs was reported to be 12%, and the 6-month overall mortality was 43.2%, with community-onset infection, secondary BSI, and vancomycin MIC≥2 g/mL being the risk factors for mortality. Although the prevalence of MRSA BSIs among cancer patients is relatively low, it did not decline over time as MRSA BSIs in the general hospital population and the high mortality rate was related to MRSA BSIs in patients with malignancy.